1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105:289–297.
2. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–530.
3. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.
4. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s Disease Activity Index (CDAI). Gastroenterology. 1979;77:843–846.
5. Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet. 1980;1:514.
6. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective muticentre study. Groupe d’Etudes Th  ́rapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983–989.
7. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.
8. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99: 956–963.
9. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.
10. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–782.
11. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behaviour of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–250.
12. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139:1147–1155.
13. D’Haens G, Fedorak R, Lemann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1599–1604.
14. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010;59:141–147.
15. D’Haens G, Baert F, van Assche G et al. Early combined immunosup- pression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371: 660–667.
16. Sharp JT, Lidsky MD, Collins LC, et al. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of 
17. Sharp JT, Bluhm GB, Brook A, et al. Reproducibility of multiple-ob- server scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum. 1985;28:16–24.
18. Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985;28: 1326–1335.
19. van der Heijde DM, van Leeuwen MA, van Riel PL. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp’s method (van der Heijde modification). J Rheumatol. 1995;22:1992–1996.
20. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 2004;63:149–155.
21. Bruynesteyn B, Landew R, van der Linden SJ, et al. Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months’ follow up. Ann Rheum Dis. 2004;63:1413–1418.
22. St Clair AW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–3443.
23. Landewe R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 2006;54: 3119–3125.
24. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis. 2007;66:1227–1232.
25. Cosnes J, de Parades V, Carbonnel F, et al. Classification of the sequelae of bowel resection for Crohn’s disease. Br J Surg. 1994;81: 1627–1631.
26. Gore RM, Balthazar EJ, Ghahremani GG, et al. CT features of ulcera- tive colitis and Crohn’s disease. AJR Am J Roentgenol. 1996;167:3–15.
27. Thoeni RF, Cello JP. CT imaging of colitis. Radiology. 2006;240: 623–638.
28. Parente F, Greco S, Molteni M, et al. Oral contrast enhanced bowel ultrasonography in the assessment of small intestine Crohn’s disease. A prospective comparison with conventional ultrasound, x ray studies, and ileocolonoscopy. Gut. 2004;53:1652–1657.
29. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn’s disease: meta-analysis. Radiology. 2005;236:95–101.
30. Maglinte DD. Science to practice: do mural attenuation and thickness at contrast-enhanced CT enterography correlate with endoscopic and histologic findings of inflammation in Crohn’s disease? Radiology. 2006;238:381–382.
31. Booya F, Fletcher JG, Huprich JE, et al. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology. 2006;241:787–795.
32. Bodily KD, Fletcher JG, Solem CA, et al. Crohn disease: mural attenuation and thickness at contrast-enhanced CT enterography—cor- relation with endoscopic and histologic findings of inflammation. Radiology. 2006;238:505–516.
33. Mak  ́ EK, Mester AR, Tarj  ́n Z, et al. Enteroclysis and spiral CT examination in diagnosis and evaluation of small bowel Crohn’s disease. Eur J Radiol. 2000;35:168–175.
34. Tarj  ́n Z, T  ́th G, Gy  ̈rke T, et al. Ultrasound in Crohn’s disease of the small bowel. Eur J Radiol. 2000;35:176–182.
35. Gourtsoyiannis N, Papanikolaou N, Grammatikakis J, et al. MR imaging of the small bowel with a true-FISP sequence after enteroclysis with water solution. Invest Radiol. 2000;35:707–711.
36. Madsen SM, Thomsen HS, Schlichting P, et al. Evaluation of treatment response in active Crohn’s disease by low-field magnetic resonance imaging. Abdom Imaging. 1999;24:232–239.
37. Koh DM, Miao Y, Chinn RJ, et al. MR imaging evaluation of the activity of Crohn’s disease. AJR Am J Roentgenol. 2001;177:1325–1332.